BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 7937279)

  • 1. Pneumocystis carinii pneumonia prophylaxis during pregnancy.
    Connelly RT; Lourwood DL
    Pharmacotherapy; 1994; 14(4):424-9. PubMed ID: 7937279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia.
    Warnock AC; Rimland D
    Pharmacotherapy; 1996; 16(6):1030-8. PubMed ID: 8947975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group.
    Chaisson RE; Keruly J; Richman DD; Moore RD
    Arch Intern Med; 1992 Oct; 152(10):2009-13. PubMed ID: 1417373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Pneumocystis carinii pneumonia in patients with AIDS.
    Wordell CJ; Hauptman SP
    Clin Pharm; 1988 Jul; 7(7):514-27. PubMed ID: 3138063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.
    Bozzette SA; Finkelstein DM; Spector SA; Frame P; Powderly WG; He W; Phillips L; Craven D; van der Horst C; Feinberg J
    N Engl J Med; 1995 Mar; 332(11):693-9. PubMed ID: 7854375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group.
    Schneider MM; Hoepelman AI; Eeftinck Schattenkerk JK; Nielsen TL; van der Graaf Y; Frissen JP; van der Ende IM; Kolsters AF; Borleffs JC
    N Engl J Med; 1992 Dec; 327(26):1836-41. PubMed ID: 1360145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients.
    Martin MA; Cox PH; Beck K; Styer CM; Beall GN
    Arch Intern Med; 1992 Mar; 152(3):523-8. PubMed ID: 1546914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine.
    Mallolas J; Zamora L; Gatell JM; Miró JM; Vernet E; Valls ME; Soriano E; SanMiguel JG
    AIDS; 1993 Jan; 7(1):59-64. PubMed ID: 8442918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens.
    Ioannidis JP; Cappelleri JC; Skolnik PR; Lau J; Sacks HS
    Arch Intern Med; 1996 Jan; 156(2):177-88. PubMed ID: 8546551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumocystis carinii pneumonia in human immunodeficiency virus-infected infants and children.
    Goodwin SD
    Pharmacotherapy; 1993; 13(6):640-6. PubMed ID: 8302691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing PCP therapy.
    Torres G; Cadman J
    GMHC Treat Issues; 1997 Oct; 11(10):3-5. PubMed ID: 11364821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Guidelines for Prevention of Pneumocystis carinii Pneumonitis in Children and Adolescents with Cancer].
    Groll AH; Ritter J; Müller FM
    Klin Padiatr; 2001 Sep; 213 Suppl 1():A38-49. PubMed ID: 11577363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group.
    Girard PM; Landman R; Gaudebout C; Olivares R; Saimot AG; Jelazko P; Gaudebout C; Certain A; Boué F; Bouvet E
    N Engl J Med; 1993 May; 328(21):1514-20. PubMed ID: 8479488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis and treatment of Pneumocystis carinii pneumonia.
    O'Doherty MJ; Bateman NT
    Br J Hosp Med; 1991 May; 45(5):277-8, 280, 283. PubMed ID: 1676607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021.
    Hardy WD; Feinberg J; Finkelstein DM; Power ME; He W; Kaczka C; Frame PT; Holmes M; Waskin H; Fass RJ
    N Engl J Med; 1992 Dec; 327(26):1842-8. PubMed ID: 1448121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pneumocystis carinii pneumonia and HIV infection: diagnosis and treatment].
    González-García J; Rubio García R; Antela López A; García Alcaide F
    Enferm Infecc Microbiol Clin; 1998; 16 Suppl 1():36-44. PubMed ID: 9859618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group.
    Thea DM; Lambert G; Weedon J; Matheson PB; Abrams EJ; Bamji M; Straus WL; Thomas PA; Krasinski K; Heagarty M
    Pediatrics; 1996 Jan; 97(1):59-64. PubMed ID: 8545225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protect yourself from Pneumocystis carinii.
    AIDS Alert; 1999 Jun; 14(6):suppl 1-2. PubMed ID: 11366414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: pathophysiology, therapy, and prevention.
    Montgomery AB
    Semin Respir Infect; 1989 Jun; 4(2):102-10. PubMed ID: 2664934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
    Mussini C; Pezzotti P; Govoni A; Borghi V; Antinori A; d'Arminio Monforte A; De Luca A; Mongiardo N; Cerri MC; Chiodo F; Concia E; Bonazzi L; Moroni M; Ortona L; Esposito R; Cossarizza A; De Rienzo B
    J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.